stopped because it was not reaching its efficacy endpoints. GeoVax
responded to the discontinuance of Merck's trial by pointing out
significant differences between the GeoVax vaccine technology and the
technology used in the Merck trial.
GeoVax AIDS vaccines advancing in human trials represent a
significantly different vaccine approach, vaccine composition and
results to date than the Merck vaccine.
* Prototypes for the GeoVax vaccines were selected from a series of
trials in non-human primates for their ability to protect against
the development of AIDS when vaccinated individuals were
administered an AIDS causing virus. At each major step along the
development pathway, GeoVax vaccines providing the best protection
against AIDS were moved forward.
* GeoVax AIDS vaccines demonstrated excellent protective results in
non-human primate models, much better protective results than
reported for Merck's vaccine in similar models. GeoVax AIDS
vaccines protected 22/23 non-human primates for over 3 1/2 years
and 5/6 non-vaccinated controls died of AIDS post-AIDS virus
* GeoVax AIDS vaccines are designed to elicit protective antibodies
(Ab) as well as protective T cells (white blood cells) against the
AIDS virus. The Merck vaccine stimulates only T cells for providing
protection and does not include the Env protein of HIV which is the
target for protective antibody (Ab).
* Protective Ab has been difficult to elicit with HIV/AIDS vaccines.
GeoVax has approached this challenge by vaccinating with the
natural form of Env (HIV envelope antigens) under conditions that
elicit tightly binding Ab. GeoVax studie
|SOURCE GeoVax Labs, Inc.|
Copyright©2007 PR Newswire.
All rights reserved